Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity...
Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET
Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as ...
France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market...
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastases Signals of tumor agnostic...
Webcast on Tuesday, October 21, 2025 at 4:00 p.m. ET
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Agenus (...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory...